We thank Tan et al for their comments on our study1; they have raised some important points about drug-coated balloon (DCB) angioplasty in vascular access treatment. Although there have been several trials focused on DCB angioplasty in the treatment of arteriovenous fistula (AVF) stenosis, there has been controversy surrounding its efficacy and safety. The higher proportion of de novo AVF lesions noted in our trial were in line with what is currently observed in China,2 and as such, we agree that this may have a positive impact on postangioplasty patency compared with recurrent lesions.